Dimensional Fund Advisors LP increased its position in Vanda Pharmaceuticals Inc. (NASDAQ:VNDA) by 104.2% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 530,705 shares of the biopharmaceutical company’s stock after purchasing an additional 270,795 shares during the period. Dimensional Fund Advisors LP’s holdings in Vanda Pharmaceuticals were worth $13,867,000 at the end of the most recent reporting period.
Other hedge funds have also recently modified their holdings of the company. BlackRock Inc. boosted its holdings in Vanda Pharmaceuticals by 78.3% in the third quarter. BlackRock Inc. now owns 8,845,222 shares of the biopharmaceutical company’s stock worth $202,999,000 after acquiring an additional 3,884,298 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Vanda Pharmaceuticals by 18.8% in the third quarter. Vanguard Group Inc. now owns 3,969,954 shares of the biopharmaceutical company’s stock worth $91,111,000 after acquiring an additional 629,086 shares in the last quarter. Vanguard Group Inc boosted its holdings in Vanda Pharmaceuticals by 18.8% in the third quarter. Vanguard Group Inc now owns 3,969,954 shares of the biopharmaceutical company’s stock worth $91,111,000 after acquiring an additional 629,086 shares in the last quarter. Macquarie Group Ltd. boosted its holdings in Vanda Pharmaceuticals by 4.9% in the third quarter. Macquarie Group Ltd. now owns 2,681,144 shares of the biopharmaceutical company’s stock worth $61,533,000 after acquiring an additional 126,140 shares in the last quarter. Finally, Glenmede Trust Co. NA boosted its holdings in Vanda Pharmaceuticals by 328,291.4% in the third quarter. Glenmede Trust Co. NA now owns 1,766,746 shares of the biopharmaceutical company’s stock worth $40,545,000 after acquiring an additional 1,766,208 shares in the last quarter. 99.33% of the stock is currently owned by institutional investors.
Several equities research analysts have commented on VNDA shares. ValuEngine downgraded Vanda Pharmaceuticals from a “buy” rating to a “hold” rating in a report on Thursday. Oppenheimer lowered their price target on Vanda Pharmaceuticals from $29.00 to $21.00 in a report on Thursday, February 14th. BidaskClub downgraded Vanda Pharmaceuticals from a “sell” rating to a “strong sell” rating in a report on Tuesday, March 12th. Stifel Nicolaus reaffirmed a “buy” rating on shares of Vanda Pharmaceuticals in a report on Wednesday, February 6th. Finally, Cantor Fitzgerald downgraded Vanda Pharmaceuticals from an “overweight” rating to a “neutral” rating and lowered their price target for the company from $38.00 to $30.00 in a report on Wednesday, February 6th. Two investment analysts have rated the stock with a sell rating, four have given a hold rating and six have given a buy rating to the stock. The stock presently has an average rating of “Hold” and a consensus price target of $34.00.
Vanda Pharmaceuticals (NASDAQ:VNDA) last announced its quarterly earnings results on Wednesday, February 13th. The biopharmaceutical company reported $0.19 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.03) by $0.22. The firm had revenue of $53.04 million for the quarter, compared to the consensus estimate of $51.56 million. Vanda Pharmaceuticals had a return on equity of 9.80% and a net margin of 13.05%. The company’s quarterly revenue was up 19.8% on a year-over-year basis. During the same period in the prior year, the company posted ($0.04) earnings per share. On average, analysts predict that Vanda Pharmaceuticals Inc. will post 0.22 EPS for the current year.
In related news, CEO Mihael Hristos Polymeropoulos sold 38,166 shares of the company’s stock in a transaction on Monday, March 4th. The stock was sold at an average price of $19.41, for a total transaction of $740,802.06. Following the completion of the sale, the chief executive officer now owns 1,217,136 shares in the company, valued at $23,624,609.76. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, CFO James Patrick Kelly sold 4,976 shares of the company’s stock in a transaction on Friday, March 1st. The shares were sold at an average price of $20.15, for a total value of $100,266.40. Following the sale, the chief financial officer now owns 218,497 shares of the company’s stock, valued at approximately $4,402,714.55. The disclosure for this sale can be found here. In the last quarter, insiders have sold 59,274 shares of company stock valued at $1,164,127. 7.80% of the stock is owned by company insiders.
About Vanda Pharmaceuticals
Vanda Pharmaceuticals Inc, a biopharmaceutical company, focuses on the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. The company's marketed products include HETLIOZ (tasimelteon), a product for the treatment of non-24-hour sleep-wake disorders; and Fanapt (iloperidone), a product for the treatment of schizophrenia.
See Also: Outstanding Shares
Want to see what other hedge funds are holding VNDA? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Vanda Pharmaceuticals Inc. (NASDAQ:VNDA).
Receive News & Ratings for Vanda Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vanda Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.